Gastrointestinal (GI) functional and motility disorders are responsible for substantive morbidity and economic impact.

Gastroparesis affects a significant number of the 24 million diabetics in the U.S; there are 2.3 million type 1 and type 2 diabetic patients with moderate or severe gastroparesis symptoms who are seeking treatment. Gastroparesis symptoms include chronic nausea, vomiting, and malnutrition and result in a significant rate of hospitalization. In people with diabetes, this condition also often undermines measures to manage hyperglycemia. Gastroparesis-related hospitalizations and emergency room visits are significant and increasing, with total annual hospital costs of $490 million in 2009.

Lower GI Functional Disorders: 15 million people in the U.S. seek medical care annually for chronic constipation and irritable bowel syndrome (IBS), and approximately 15% are refractory to existing therapies. These conditions are two of the most common GI motility disorders, with significant health consequences. There is a compelling need for new treatments for lower GI functional disorders, but there are no safe and effective prokinetic drugs currently approved for these conditions in the U.S.